SCHEMBL4245780

SCHEMBL4245780

Cc1ccc(Cl)c(C(=O)N2CCC(Nc3cnc4ccc(Cl)cc4n3)C2)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNK O75909 9/20 0.44
CDK12 Q9NYV4 9/20 0.44
CCNA2 P20248 6/20 0.44
CDK2 P24941 6/20 0.44
CDK7 P50613 6/20 0.44
CCNH P51946 6/20 0.44
MNAT1 P51948 6/20 0.44
JAK3 P52333 3/20 0.44
NOS1 P29475 1/20 0.42
NOS2 P35228 1/20 0.42
PDE2A O00408 1/20 0.42
GFER P55789 1/20 0.42
KMT2A Q03164 1/20 0.42
TSHR P16473 2/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
AURKA O14965 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4245775 1.00 CCNK (0.44) CCNKCDK12CCNA2CDK2CDK7
SCHEMBL4239234 0.96 CCNK (0.44) CCNKCDK12CCNA2CDK2CDK7
SCHEMBL3659844 0.96 CCNK (0.44) CCNKCDK12CCNA2CDK2CDK7
SCHEMBL4238382 0.91 HCRTR1 (0.49) CCNKCDK12CCNA2CDK2CDK7
SCHEMBL4238388 0.91 HCRTR1 (0.49) CCNKCDK12CCNA2CDK2CDK7
SCHEMBL8224532 0.90 PDGFRB (0.45) CCNKCDK12CCNA2CDK2CDK7
SCHEMBL4244736 0.89 GFER (0.45) CCNKCDK12CCNA2CDK2CDK7
SCHEMBL4244738 0.89 GFER (0.45) CCNKCDK12CCNA2CDK2CDK7
SCHEMBL8227779 0.89 HCRTR1 (0.46) CCNKCDK12CCNA2CDK2CDK7
SCHEMBL8224408 0.87 PDGFRB (0.45) CCNKCDK12CCNA2CDK2CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897627-B2 Heteroaryl derivatives as orexin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2011-03-01 US disclosed
US-20090163485-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163485-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR1, HCRTR2, MTNR1A CCNK 2064/4885CDK12 1049/4885CCNA2 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.